Sign inJoin waitlistJoin the waitlist

KN

Kiran Naqvi

Associate Professor — Division of Hematology and Oncology, Medicine · University of California

Credentials: · · · · · · ·

History

University of California
Present
University of California
Present

UT MD Anderson
2007–2008
University of Texas M D Anderson Cancer Center
2004–2007
Internal Medicine
2001–2004
Dow Medical College
1997–2001

Research

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · 280 citations
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 201 citations
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2022 · 173 citations

Hagop Kantarjian
49 papers
Guillermo Garcia-Manero
43 papers
Elias Jabbour
41 papers
Tapan Kadia
36 papers
GB
Gautam Borthakur
33 papers
Naval Daver
33 papers
Courtney DiNardo
31 papers
Jorge Cortes
28 papers
Marina Konopleva
27 papers
Naveen Pemmaraju
26 papers
KS
Koji Sasaki
22 papers
Yesid Alvarado
19 papers

Clinical trials

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1, Phase 2
Delta-Fly Pharma, Inc.
2024–2026